Radial endobronchial ultrasound-assisted transbronchial needle aspiration for pulmonary peripheral lesions in the segmental bronchi adjacent to the central airway.

BACKGROUND: Tissue samples from lesions located in the 3rd to 5th segmental bronchi are challenging to obtain. In this retrospective study, we aimed to evaluate the diagnostic rate of pulmonary peripheral lesions located in the 3rd to 5th segmental bronchi, near the inner field of lung on the computed tomography (CT) image and outside the bronchus, using radial endobronchial ultrasound (REBUS) followed by transbronchial needle aspiration (TBNA).
METHODS: This retrospective study enrolled patients whose preoperative CT examinations showed a lesion located in the segmental bronchi (3rd to 5th), yet adjacent to the inner field of lung on the CT image. REBUS followed by TBNA was used to acquire tissue samples from these lesions. A bronchoscope was used to reach the bronchi surrounding the lesion, and an ultrasound probe was used to determine the lesion's location. Then, the ultrasound probe was withdrawn, and puncture was performed at the location that was determined by ultrasound. The tissue specimens obtained were subjected to pathological examination.
RESULTS: Nineteen patients were enrolled in this study including 15 males and 4 females with an average age of 55 years old. Of the enrollees, 8 patients (42.1%) were successfully diagnosed with samples obtained through TBNA, including 6 cases of lung cancer, 1 case of non-specific inflammation, and 1 case of cryptococcal infection. The diagnostic rate was 42.1%. No post-procedural complications were observed among the patients. There was no significant difference in nodule diameter between patients with a diagnostic sample and those in whom TBNA failed to provide a diagnosis (2.99±0.96 vs. 2.26±1.27 cm, P=0.20).
CONCLUSIONS: With the assistance of REBUS, TBNA can acquire sufficient samples to achieve a reasonably diagnostic rate for parenchymal lung lesions located near the inner field of lung on the CT image without intrabronchial invasion. 2021 Translational Lung Cancer Research. All rights reserved.

Introduction

Lung cancer ranks first out of all malignancies for morbidity and mortality in most countries (1,2). Early diagnosis and treatment are key to curing lung cancer and prolonging survival. The American National Lung Screening Trial (NCT00047385) demonstrated that screening with low-dose computed tomography (CT) lead to a relative reduction in mortality of 20% among patients with lung cancer (3). Consequently, this screening method has been accepted by the academic community and included in clinical guidelines. With large-scale CT screening, an increasing number of unidentified lung lesions appears to be occurring (4,5). Therefore, the optimal diagnostic approach for patients with suspicious nodules urgently needs to be determined.

Malignant diseases cannot be accurately distinguished from benign conditions by noninvasive examination methods, such as fluorodeoxyglucose positron emission tomography or dynamic contrast-enhanced CT (6). For such indeterminate lung nodules, many invasive methods for obtaining tissue exist. Probably the most widely available, CT-guided lung biopsy is associated with a high incidence of complications (up to 40%), with the incidence of pneumothorax reaching up to 25% (7,8).

Many minimally invasive flexible bronchoscopic procedures are currently available. These include convex probe endobronchial ultrasound (CP-EBUS), radial endobronchial ultrasound (REBUS), virtual bronchoscopy (VB), and electromagnetic navigation bronchoscopy (ENB). However, the availability of ENB and VB remains extremely limited in many parts of the world, mostly due to the elevated costs of these procedures. The access to these lesions in the vicinity of the 3rd to 5th segmental bronchi by CP-EBUS may be limited by the scope’s large size (6.9 mm in diameter). Finally, when no endobronchial component or extrinsic compression is present, adequate sampling is generally limited to transbronchial needle aspiration (TBNA). TBNA has been widely used in diagnosing both benign and malignant pulmonary diseases. EBUS is a good approach for visualizing lesions to guide the sample biopsy and EBUS-TBNA has been suggested to have a sensitivity around 0.9 and a specificity to 1.0 in lung cancer diagnosing and staging (9,10). Currently, REBUS has been developed as a novel technique to guide TBNA sampling (11). In this retrospective study, we aimed to evaluate the diagnostic rate and complications when using REBUS followed by TBNA in the evaluation of lesions located in the 3rd to 5th segmental bronchi, near the inner lung field on the CT image and outside the bronchus. We present the following article in accordance with the STROBE reporting checklist (available at https://dx.doi.org/10.21037/tlcr-21-490).

Methods

Study participants

Patients who underwent REBUS-TBNA in Shanghai Pulmonary Hospital between August 2016 and May 2020 were included in this retrospective study. During this time, 900 patients underwent REBUS in the hospital. Because of the specific location of the lesion, nineteen out of 900 patients conformed to the inclusion criteria (Figure S1). Clinical and pathological parameters including the patient’s age, sex, smoking history, the lesion location and the lesion size were recorded from patients’ medical records and medical images.

The inclusion criteria for patients were: (I) aged 18 to 80 years old; (II) clinically suspected lung lesion located in the segmental bronchi (3rd to 5th) in addition to its location near the inner lung field on the CT image; (III) no contraindications to bronchoscopy; (IV) signed an informed consent form and approval for medical record reviewing. The study received approval from the Ethics Committee of Tongji University Affiliated Shanghai Pulmonary Hospital (No. 18Q016NJ) in accordance with the guidelines of the Helsinki Declaration (as revised in 2013). Written informed consents were obtained from all patients for reviewing their medical records and images for scientific research.

REBUS-TBNA

Preoperative investigations included an enhanced CT scan of the lungs, complete blood count (CBC), liver and renal function examination, electrolytes examination, electrocardiogram (ECG), and coagulation tests. Immediately before the procedure, the operator reviewed the chest CT images and determined the lesions size and the bronchus in which was located. The patient was instructed to lie on the examination table in the supine position and received nebulized lidocaine (administered oropharyngeally) as local anesthesia. Then oxygen was provided via nasal cannula for the entire length of the procedure and monitored for vital signs. In our current cohort intravenous sedation or general anesthesia was not applied.

The procedure was performed with the Olympus BF-P260F bronchoscope (Olympus Co. Ltd., Tokyo, Japan). After a systematic inspection of the tracheobronchial tree (), the REBUS (UM-S20-20R, Olympus Co. Ltd., Tokyo, Japan) 20-MHz probe was inserted into the target bronchus on the bases of the CT-scan images as discussed above. Once the best possible ultrasound image of the peribronchial lesion was obtained with the REBUS probe (), the segmental bronchus was recorded, and the optimal puncture location was selected. Before the withdrawal of the ultrasound probe, the probe depth was marked. Subsequently, a 19-gauge WANG TBNA needle (MWF-319, ConMed Company, New York, USA) was inserted through the biopsy channel at the same length of the mark done on the REBUS probe, and a needle biopsy was performed at the location that was selected under ultrasound image (). Then, a 60-mL syringe was attached to the end of the needle with negative pressure aspiration applied. The process was repeated to obtain 5 to 6 samples. Brush cytology was performed routinely to avoid missing any mucosal involvement by the lesion not macroscopically identified on the airway exam. Biopsy tissues would be sent for histopathological examination and smear cytological examination. If an accurate diagnosis could be obtained from the biopsy sample, the sample would be considered as a diagnostic sample and the patient would be defined as patient with positive diagnosis.

Figure 1

The representative images during REBUS-TBNA procedure. (A) Bronchoscopic image of the right middle lobe bronchus of a patient; (B) radial ultrasound image of a lesion in the right middle lobe; (C) puncture of the right middle lobe lesion. REBUS, radial endobronchial ultrasound; TBNA, transbronchial needle aspiration.

The specimens were fixed in a 10% formalin solution for histopathological examination. The molecular testing was polymerase chain reaction (PCR)-based assay. DNA or RNA would be extracted from biopsy samples according to the protocol. Reverse transcription would be done to convert RNA into cDNA for further PCR. The aberrations of EGFR/ALK/ROS1/KRAS/BRAF were detected by Multi-Gene Mutations Detection Kit (Amoy, Xiamen, China) according to manufacturer’s protocol.

After the procedure, if bleeding occurred, local hemostasis was carried out using diluted epinephrine and cold saline. After confirmation of no active bleeding, the procedure was completed. Intraoperative and postoperative adverse events were recorded including bleeding, chest pain, hypoxia, and postoperative infection. All procedures were performed by the same bronchoscopist, who was aided by the same nurse, to avoid the potential bias.

Statistical analyses

Data were statistically analyzed with IBM SPSS Statistics 22 (IBM, Armonk, NY, USA). Continuous variables were expressed as mean ± standard deviation, and categorical variables as counts and percentages. Fisher’s exact test was used to compare the distributions of sex, age, smoking history, and nodule diameters between groups. Nodule diameters for patients with different diagnoses (“positive” or “negative”) were compared using the t-test. Statistical significance was indicated by a P value of less than 0.05. The diagnostic yield was calculated by dividing the number of successful diagnoses by the total number of lesions.

Results

This study included 19 patients [15 males (78.9%)], with an average age of 55 (±12.1) years old (). All patients had their reports of pathological examination and were included for further analysis. Eight nodules were located in the left lung, of which only one was in the left lower lobe. Of the eleven right lung nodules, six were located in the right upper lobe, one in the right middle lobe and four in the right lower lobe (). Lesion size was obtained from the CT images and the average diameter of all lesions was 2.57±1.18 cm (). No bronchus sign was observed on CT images in any patients. All lung nodules were visualized under REBUS during the procedure.

Table 1

Clinical characteristics of patients with lung lesions

Patient No.	Sex	Age (years)	Smoker	Lesion diameter (cm)	Lesion location	Pathology	Diagnosis
1	M	50	No	2.1	RUL, B3a	Adenocarcinoma	P
2	M	52	No	1.3	RLL, B6	ND	N
3	F	45	No	3.1	LUL, B5	Inflammation	P
4	M	56	No	3.8	RUL, B2b	Cryptococcal infection	P
5	M	73	No	0.6	LUL, B4	ND	N
6	M	33	No	2.5	RLL, B6	ND	N
7	M	48	No	2.5	RLL, B8	ND	N
8	M	52	No	4.0	LUL, B3	ND	N
9	M	60	Yes	1.2	LUL, B1	ND	N
10	M	59	Yes	4.6	LUL, B3	ND	N
11	M	55	Yes	2.1	RUL, B2a	Adenocarcinoma	P
12	F	65	No	1.9	LLL, B10	ND	N
13	M	53	Yes	3.9	LUL, B3	Carcinoma	P
14	F	56	No	2.7	RML, B4	ND	N
15	F	25	No	0.8	RUL, B2	ND	N
16	M	65	No	4.3	LUL, B1	Adenocarcinoma	P
17	M	67	No	2.8	RUL, B1	ND	N
18	M	69	No	1.7	RUL, B2	Adenocarcinoma	P
19	M	66	No	2.9	RLL, B8	Small cell lung cancer	P

M, male; F, female; RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe; ND, non-diagnostic; P, positive diagnosis; N, negative diagnosis.

In total, 8 patients (42.1%) were successfully diagnosed with TBNA samples and most of these were malignant (). Six cases were ultimately diagnosed with lung cancer, one with cryptococcal infection, and one with non-specific inflammation. Two brush samples (10.5%) were diagnostic and showed lung adenocarcinoma. The overall diagnostic rate was 42.1% [8/19]. Among the patients with a positive diagnosis, 3 lesions were in the left upper lobe, 4 lesions in the right upper lobe, and 1 lesion in the right lower lobe. Meanwhile, in the 6 samples diagnosed as lung cancer, 3 samples were also suitable for detecting driver gene alteration (EGFR/ALK/BRAF/KRAS/ROS1). One of these was found to have BRAF V600E mutation and no driver gene alteration was detected in the other two. Among patients with a negative diagnosis, 1 lesion was in left lower lobe, 4 lesions in left upper lobe, 3 lesions in right lower lobe, 1 lesion in right middle lobe and 2 lesions in right upper lobe.

No significant difference was found in nodule diameter between patients with a positive and negative diagnoses (2.99±0.96 vs. 2.26±1.27 cm, P=0.20). Other clinical characteristics were also similar between diagnostic and non-diagnostic samples (P>0.05, ). Furthermore, no postoperative complication was recorded among the study participants.

Table 2

Comparison of clinical parameters according to diagnostic status (positive or negative)

Group	Positive	Negative	Total	P value
Sex				0.60
Male	7	8	15 (78.9)
Female	1	3	4 (21.1)
Age (years)				1.00
≤55	4	5	9 (47.4)
>55	4	6	10 (52.6)
Smoking history				1.00
Non-smoker	6	9	15 (78.9)
Smoker	2	2	4 (21.1)
Lesion diameter (cm)				0.37
≤2.5	3	7	10 (52.6)
>2.5	5	4	9 (47.4)

Discussion

The present study included 19 patients with peribronchial lesions located in the vicinity of the 3rd to 5th segmental bronchi, near the inner field of the lung on the CT image and outside the airway lumen. Obtaining tissue samples from such lesions can be challenging. The airway diameter may not be large enough to be able to fit a CP-EBUS for real-time sampling. Also, as the lesions are often completely outside the airway, endobronchial forceps biopsy and brush techniques are not good options. As a result, conventional TBNA (C-TBNA) may turn out to be the only available tool for obtaining pathological tissue samples in many of these cases (11). C-TBNA was first invented by Dr. Eduardo Schieppati in 1949 and was further developed by Ko-Pen Wang (12). It has been applied successfully in the clinical setting for more than 20 years. With the guidance of REBUS described herein, C-TBNA remains a valuable tool.

In the current study, the diagnostic yield of REBUS for nodules with an average diameter of 2.57 cm near the inner field of the lung was 42.1%. A retrospective analysis of 177 patients revealed diagnostic rates of 14% and 31% for lesions of <2 cm located in the peripheral third and the inner two-thirds of the lung, respectively (13), which almost corresponded with our results. Ost and colleagues have described the diagnostic yield of REBUS to be 57.0% with a higher diagnostic yield for lesions greater than 2 cm in longest diameter (14). A prospective trial with 54 patients with nodules that could not be visualized by fluoroscopy reported 48 lesions (89%) were localized by REUBS, and in 38 cases (70%) diagnoses were established by biopsy. One pneumothorax occurred in this series (15). In another study, the diagnostic yield of REBUS was 70.6% (16), which was superior to that previously reported for routine bronchoscopy (13,17). Wang Memoli et al. also reported the diagnostic yield of REBUS to be 71.1% in a meta-analysis (18). Moreover, the currently reported diagnostic yield of REBUS was comparable to that reported by Gildea et al. for ENB (74%) (19) and Asano et al. for VB (67.1%) (20). It suggests that REBUS-TBNA is an efficient and cost-effective diagnostic method. In our study, we only included nodules located in the inner field of the lung. The prevalence of such lesions in previous studies is not well described. Thus, the relatively low diagnostic yield in our study might be related to the very specific location of the lesions. Further studies are indispensable to evaluate the diagnostic performance of REBUS for lesions at different segmental bronchi. Meanwhile, according to our current study, the sample obtained from REBUS-TBNA may also suitable for molecular testing, which is corresponding to previous study (21).

The diagnostic sensitivity of trans-bronchoscopic biopsy for peripheral lung cancer has been shown to be related to lesion size (13,22). With traditional EBUS, the larger the lesion, the greater the likelihood of obtaining a diagnostic sample (23). A recent meta-analysis of 57 studies indicated that the diagnostic rate was significantly higher for lesions with a diameter of >2 cm (16). In this study, we found that the nodule size did not differ significantly between patients with diagnostic and non-diagnostic samples. However, because of the small sample size of our study, these findings need to be interpreted with caution and larger studies are needed.

In a study of 846 CT-guided percutaneous procedures, the mean lesion size was 3.02 cm and the complications rate was 30%, with the incidence of pneumothorax and hemoptysis reaching 27% and 3%, respectively (24). The risk of pneumothorax is 11 times higher in patients with lesions <2 cm than in patients with lesions >4 cm (25). The rate of pneumothorax during routine bronchoscopy is reported to be 4% (26,27). The risk of complications from REBUS is quite low, with an approximate risk of pneumothorax of only 1% (28), which was in line with our research findings. Furthermore, the incidence of adverse events requiring intervention is only 0.7% (18).

Although REBUS-TBNA can improve the diagnosis of those lesions located in 3rd–5th segmental bronchus, it has certain shortcomings. For instance, radial ultrasound is not self-navigating or localizing, and its path of exploration depends on the operator’s individual understanding of lesion localization. Previous studies reported that approximately 25.0% to 33.3% of lesions were undefined (29,30).

Our study also had some limitations. First, the small sample size, the single-center and retrospective nature of the present study. Second, the patient without identical lesion under REBUS was not included in the study. Third, due to the lack of long-term follow-up, true sensitivities could not be calculated. Also, there was a higher number of non-smokers in our cohort which might suggest a larger than usual number of benign etiologies. This could have impacted our diagnostic yield as a TBNA technique is not as sensitive for benign disease as it is to malignant lesions. Finally, sampling of these nodules with CP-EBUS was not attempted. It has been shown that some of these lesions can be sampled with CP-EBUS even when the nearby airway diameter is smaller than the scope (31). Perhaps the CP-EBUS scope dilates the airway to a certain extent. So, it is possible REBUS and CP-EBUS may be complementary for lesions such as the ones described in our report. Especially for upper lobe lesions where the currently available CP-EBUS does not perform well.

Conclusions

REBUS-TBNA is a minimally invasive biopsy technique with a reasonable diagnostic rate for more central lesions and a low incidence of complications. TBNA can be used with new guided instrumentation, and more flexible dedicated peripheral tools may further improve diagnostic rates. In addition, REBUS-TBNA has emerged in the field of tumor precision therapy and it may eventually play a significant role in accurate concomitant tumor detection, typing, and treatment (21,32,33). Our future work will continue to explore and improve the clinical value of REBUS-TBNA.

The article’s supplementary files as